GM-CSF derived from tumor cells increases miR-200c levels in MDSCs and miR-200c, in turn, promotes the expansion and immunosuppressive activity of MDSCs by targeting PTEN and FOG2. Specifically, in vivo experiments have shown that miR-200c can remarkably promote tumor growth by modifying MDSCs (70). The gene discussed is CSF2; the disease is neoplasm.